Alembic Pharma acquires US-based drug developer Orbit Labs

Alembic Pharma today announced that it has completed the acquisition of US-based generic drug developer Orbit Laboratories LLC, along with its real estate owned by Okner Realty LLC.

Why Alembic acquires Orbit Laboratories?

• This acquisition increases Alembic’s US product portfolio with seven approved ANDAs and four ANDAs pending approvals. It also increases Alembic’s breadth and capabilities in the US with a competent R&D team bringing complementary skill sets in soft gelatin based oral solids and oral liquids.